Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nektar Continues To Refocus With Sale Of Pulmonary Business To Novartis

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Howard Robin says firm now will focus fully on PEGylation and conjugate chemistry-based drug development.

You may also be interested in...



Nektar Dips Into AstraZeneca's Deep Pockets With OIC Deal

As Nektar reinvents itself, the specialty drug developer gets multi-million dollar validation from AstraZeneca in deal for NKTR-118.

Nektar Dips Into AstraZeneca's Deep Pockets With OIC Deal

As Nektar reinvents itself, the specialty drug developer gets multi-million dollar validation from AstraZeneca in deal for NKTR-118.

No Sales Model Left Behind: Novartis Joins Firms In Changing Market Focus

Novartis is joining the horde of pharmaceutical companies that are revamping their sales and marketing organizations in response to a U.S. market that is rapidly changing, at varying paces in different regions

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel